{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:25:05Z","timestamp":1787016305902,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1124\/jpet.108.149054","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T20:46:10Z","timestamp":1230065170000},"page":"723-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease"],"prefix":"10.1016","volume":"328","author":[{"given":"Satoshi","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hwa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Mannen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.108.149054_bib1","doi-asserted-by":"crossref","unstructured":"Asano N, Ishii S, Kizu H, Ikeda K, Yasuda K, Kato A, Martin OR, and Fan JQ (2000) In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267: 4179-4186.","DOI":"10.1046\/j.1432-1327.2000.01457.x"},{"key":"10.1124\/jpet.108.149054_bib2","doi-asserted-by":"crossref","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, and Laster L (1967) Enzymatic defect in Fabry\u2019s disease: ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167.","DOI":"10.1056\/NEJM196705252762101"},{"key":"10.1124\/jpet.108.149054_bib3","unstructured":"Desnick RJ, Ioannou YA, and Eng CM (2001) \u03b1-Galactosidase A deficiency: Fabry disease, in The Metabolic and Molecular Bases of Inherited Disease (Scriver CR, Beaudet AL, Sly WS, and Valle D, eds) pp 3733-3774, McGraw-Hill, New York."},{"key":"10.1124\/jpet.108.149054_bib4","doi-asserted-by":"crossref","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, et al. (2001a) A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722.","DOI":"10.1086\/318809"},{"key":"10.1124\/jpet.108.149054_bib5","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, and Desnick RJ (2001b) Safety and efficacy of recombinant human alphagalactosidase A-replacement therapy in Fabry\u2019s disease. N Engl J Med 345: 9-16.","DOI":"10.1056\/NEJM200107053450102"},{"key":"10.1124\/jpet.108.149054_bib6","doi-asserted-by":"crossref","unstructured":"Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24: 355-360.","DOI":"10.1016\/S0165-6147(03)00158-5"},{"key":"10.1124\/jpet.108.149054_bib7","doi-asserted-by":"crossref","unstructured":"Fan JQ (2007) Introduction: pharmacological chaperone therapy for lysosomal storage disorders: leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins. FEBS J 274: 4943.","DOI":"10.1111\/j.1742-4658.2007.06043.x"},{"key":"10.1124\/jpet.108.149054_bib8","doi-asserted-by":"crossref","unstructured":"Fan JQ (2008) A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 389: 1-11.","DOI":"10.1515\/BC.2008.009"},{"key":"10.1124\/jpet.108.149054_bib9","doi-asserted-by":"crossref","unstructured":"Fan JQ and Ishii S (2007) Active-site-specific chaperone therapy for Fabry disease. FEBS J 274: 4962-4971.","DOI":"10.1111\/j.1742-4658.2007.06041.x"},{"key":"10.1124\/jpet.108.149054_bib10","doi-asserted-by":"crossref","unstructured":"Fan JQ, Ishii S, Asano N, and Suzuki Y (1999) Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5: 112-115.","DOI":"10.1038\/4801"},{"key":"10.1124\/jpet.108.149054_bib11","doi-asserted-by":"crossref","unstructured":"Hamanaka R, Shinohara T, Yano S, Nakamura M, Yasuda A, Yokoyama S, Fan JQ, Kawasaki K, Watanabe M, and Ishii S (2008) Rescue of mutant alphagalactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. Biochim Biophys Acta 1782: 408-413.","DOI":"10.1016\/j.bbadis.2008.03.001"},{"key":"10.1124\/jpet.108.149054_bib12","doi-asserted-by":"crossref","unstructured":"Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, and Fan JQ (2007) Mutant alpha-galactosidase A enzymes identified in Fabry patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406: 285-295.","DOI":"10.1042\/BJ20070479"},{"key":"10.1124\/jpet.108.149054_bib13","doi-asserted-by":"crossref","unstructured":"Ishii S, Kase R, Sakuraba H, Fujita S, Sugimoto M, Tomita K, Semba T, and Suzuki Y (1994) Human \u03b1-galactosidase gene expression: significance of two peptide regions encoded by exons 1-2 and 6. Biochem Biophys Acta 1204: 265-270.","DOI":"10.1016\/0167-4838(94)90017-5"},{"key":"10.1124\/jpet.108.149054_bib14","doi-asserted-by":"crossref","unstructured":"Ishii S, Kase R, Sakuraba H, Taya C, Yonekawa H, Okumiya T, Matsuda Y, Mannen K, Takeshita M, and Suzuki Y (1998) \u03b1-Galactosidase transgenic mouse: Heterogeneous gene expression and posttranslational glycosylation in tissues. Glycoconj J 15: 591-594.","DOI":"10.1023\/A:1006915926732"},{"key":"10.1124\/jpet.108.149054_bib15","doi-asserted-by":"crossref","unstructured":"Ishii S, Yoshioka H, Mannen K, Kulkarni AB, and Fan JQ (2004) Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta 1690: 250-257.","DOI":"10.1016\/j.bbadis.2004.07.001"},{"key":"10.1124\/jpet.108.149054_bib16","doi-asserted-by":"crossref","unstructured":"Nakamura G, Maruyama H, Ishii S, Shimotori M, Kameda S, Kono T, Miyazaki J, Kulkarni AB, and Gejyo F (2008) Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice. Mol Biotechnol 38: 109-119.","DOI":"10.1007\/s12033-007-9008-5"},{"key":"10.1124\/jpet.108.149054_bib17","doi-asserted-by":"crossref","unstructured":"Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, et al. (1997) \u03b1-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 94: 2540-2544.","DOI":"10.1073\/pnas.94.6.2540"},{"key":"10.1124\/jpet.108.149054_bib18","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, and Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749.","DOI":"10.1001\/jama.285.21.2743"},{"key":"10.1124\/jpet.108.149054_bib19","doi-asserted-by":"crossref","unstructured":"Shin SH, Murray GJ, Kluepfel-Stahl S, Cooney AM, Quirk JM, Schiffmann R, Brady RO, and Kaneski CR (2007) Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun 359: 168-173.","DOI":"10.1016\/j.bbrc.2007.05.082"},{"key":"10.1124\/jpet.108.149054_bib20","doi-asserted-by":"crossref","unstructured":"Takita K, Shimada T, Kitamura H, Fujii S, and Nakamura M (1990) Studies on the physical developer for use in immunohistochemistry. Acta Histochem Cytochem 23: 647-662.","DOI":"10.1267\/ahc.23.647"},{"key":"10.1124\/jpet.108.149054_bib21","doi-asserted-by":"crossref","unstructured":"Tropak MB and Mahuran D (2007) Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells. FEBS J 274: 4951-4961.","DOI":"10.1111\/j.1742-4658.2007.06040.x"},{"key":"10.1124\/jpet.108.149054_bib22","doi-asserted-by":"crossref","unstructured":"Yu Z, Sawkar AR, and Kelly JW (2007) Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 274: 4944-4950.","DOI":"10.1111\/j.1742-4658.2007.06042.x"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524348244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524348244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.108.149054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:51:55Z","timestamp":1739987515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524348244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0022356524348244"],"URL":"https:\/\/doi.org\/10.1124\/jpet.108.149054","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.108.149054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}